Abstract 104P
Background
Gastrointestinal stromal tumor (GIST) is a rare type of soft tissue sarcoma that most commonly arises from gastric mesenchymal cells. This study represents the first-ever form of GIST registry or database in Lebanon. The aim of this study is to describe and compare the Lebanese cohort of GIST cases and their management to the findings of international reports and gold standards.
Methods
This is a retrospective medical chart review of GIST cases diagnosed at the American University of Beirut Medical Center and Hammoud Hospital University Medical Center between the years 1996 and 2017.
Results
The database includes 106 GIST cases with a median age of 63.5 years (24-90). The median tumor size is 6 cm (0.3-21) with the most common presenting symptoms being abdominal pain and anemia. Endoscopy is the most commonly utilized diagnostic modality (49%) with confirmatory biopsy done in 42% of the cases. The most common tumor location is gastric (56.7%) followed by the small intestine (32.7%) and colon (7.7%). Noteworthy, the most common tumor size in females is between 5-10cm while in males is between 2-5cm. The most common cell type identified is the spindle cell (65.7%). CD 117 and CD 34 are positive in 91% and 78% of the cases, respectively. Only 14.7% of the cases received neoadjuvant therapy in the form of chemo- or targeted therapy while 31% received adjuvant therapy in either form. For cases that received adjuvant imatinib or sunitinib, the median tumor size is 8.8cm (4-20cm). Most patients (91%) underwent surgery, either by laparotomy (66%) or laparoscopy (34%). Of those, 97.7% had negative surgical margins. Recurrence occurred in 18.7% of cases with regional and distant recurrence occurring equally (35%) versus local recurrence (30%). The 3- and 5-year disease-free survival is 80% and 76% respectively.
Conclusions
Findings from this collaborative study add to the international epidemiology of GIST. It also shows that GIST features, as well as medical and surgical practices in this Lebanese cohort, conform with those reported from other populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
110P - Neutrophil to lymphocyte ratio as a predictor of poor prognosis in advanced esophageal cancer
Presenter: Chaichana Chantharakhit
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
112P - Prognostic role of sarcopenia before neoadjuvant chemoradiotherapy in patients with esophageal cancer: A retrospective study
Presenter: Mastaneh Sanei
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02